美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床观察

Clinical observation of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure

目的探讨和观察美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床观察。方法选择2017年1月~2018年1月住院治疗的冠心病心力衰竭患者80例进行观察和分析,随机分为观察组和对照组,每组40例。两组均予常规对症治疗,对照组同时联合美托洛尔,观察组在对照组基础上同时联合曲美他嗪。两组均连续治疗6个月。治疗后对比分析两组的临床疗效及心电图改善情况。结果观察组患者治疗后的总有效率为97.5%,显著高于对照组患者治疗后的总有效率70.0%,两组临床疗效比较,差异具有显著性(P<0.05)。观察组患者心电图改善的总有效率为95.0%,显著高于对照组的72.5%,两组心电图改善的疗效对比,差异具有显著性(P<0.05)。观察组和对照组患者治疗前LVEF比较,差异不显著,治疗后观察组和对照组患者的LVEF分别为(50.3±7.2)%、(45.1±4.3)%,且观察组的LVEF显著高于对照组,组间对比分析显示差异显著(P<0.05)。结论美托洛尔联合曲美他嗪治疗冠心病心力衰竭疗效确切,心电图改善显著,临床症状明显缓解,值得临床推广和应用。

Objective To investigate and observe the clinical observation of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure. Methods Eighty coronary heart disease patients with heart failure who were hospitalized from January 2017 to January 2018 were enrolled and analyzed. They were randomly divided into observation group and control group, with 40 cases in each group. Both groups were treated with conventional symptomatic treatment. The control group was combined with metoprolol, and the observation group was combined with trimetazidine on the base of the control group. Both groups were treated continuously for 6 months. After treatment, the clinical efficacy and improvement of ECG were compared between the two groups. Results The total effective rate of the observation group was 97.5% after treatment, which was significantly higher than 70.0% of the control group after treatment. The difference in the clinical efficacy between two groups was statistically significant(P<0.05). The total effective rate of electrocardiogram improvement in the observation group was 95.0%, which was significantly higher than that in the control group(72.5%). The difference in electrocardiogram improvement between the two groups was significant(P<0.05). There was no significant difference in LVEF between the observation group and the control group before treatment. The LVEF of the observation group and the control group was(50.3±7.2)%,(45.1±4.3)%, and the LVEF of the observation group was significantly higher than that of the observation group. The comparison between groups showed significant difference(P<0.05). Conclusion Metoprolol combined with trimetazidine is effective in the treatment of coronary heart disease and heart failure. The electrocardiogram has significant improvement, and the patient's clinical symptoms have obvious relief. It is worthy of clinical promotion and application.